Evidence map›Paper›PMID 37344170›Full record

ArticleJournal of clinical pathology2024

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study.

Federica Miglietta, Valentina Carraro, Ottavia Amato, Gaia Griguolo, Michele Bottosso, Giada Munari, Giovanni Zarrilli, Marcello Lo Mele, Caterina Barbieri, Angelo Paolo Dei Tos and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Federica MigliettaDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy federica.miglietta@unipd.it.ORCID http://orcid.org/0000-0001-6203-874X
Valentina CarraroPathology Unit, Azienda ULSS 3 Serenissima, Venezia, Italy.
Ottavia AmatoDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.ORCID http://orcid.org/0000-0002-3690-8542
Gaia GriguoloDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.
Michele BottossoDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.
Giada MunariVeneto Institute of Oncology, Padova, Italy.
Giovanni ZarrilliDepartment of Medicine - DIMED - Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.
Marcello Lo MeleSurgical Pathology Unit, University Hospital of Padua, Padua, Italy.
Caterina BarbieriDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.
Angelo Paolo Dei TosDepartment of Medicine - DIMED - Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.
Maria Vittoria Dieci *Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy.
Matteo Fassan *Veneto Institute of Oncology, Padova, Italy.ORCID http://orcid.org/0000-0001-6515-5482

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHormone receptor-positive (HR)+/HER2- breast cancer (BC) is highly heterogeneous, with PI3K/PTEN/mTOR pathway alterations emerging as possible players within this complexity. We longitudinally tracked PI3K/PTEN/mTOR pathway dynamics from baseline biopsy to residual disease (RD)-and to metastases in case of relapse-in HR+/HER2- BC patients receiving neoadjuvant chemotherapy (NACT).

methodsHR+/HER2- BC patients with RD after NACT were identified. We assessed

results92 patient were included. The conversion rate of

conclusionsWe observed that PI3K/PTEN/mTOR pathway is highly dynamic under NACT exposure and the assessment of

Indexed as

Breast NeoplasmsClass I Phosphatidylinositol 3-KinasesNeoadjuvant TherapyNeoplasm, ResidualSignal TransductionAdultAgedBiomarkers, TumorChemotherapy, AdjuvantDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedMutationPhosphatidylinositol 3-KinasesBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMTOR protein, humanPhosphatidylinositol 3-KinasesPIK3CA protein, humanPTEN PhosphohydrolasePTEN protein, humanReceptors, EstrogenReceptors, ProgesteroneTOR Serine-Threonine KinasesBREAST CANCERIMMUNOHISTOCHEMISTRYNEOPLASMS

Identifiers

PMID37344170
PMCPMC11503171

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.